Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 24158386)

1.

GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.

Hawkes EA, Barton S, Cunningham D, Peckitt C, Chua S, Wotherspoon A, Horwich A, Potter M, Ethel M, Dearden C, Chau I.

Ann Hematol. 2014 May;93(5):827-34. doi: 10.1007/s00277-013-1930-y. Epub 2013 Oct 26.

PMID:
24158386
2.

Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?

Todd T, Raj S, Camilleri D, Stafford G, Bulusu R, Follows G, Williams M, Marcus R.

Ann Hematol. 2009 Nov;88(11):1107-12. doi: 10.1007/s00277-009-0734-6. Epub 2009 May 6.

PMID:
19418054
3.

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D.

Br J Haematol. 2003 Mar;120(6):970-7.

PMID:
12648066
4.

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB.

Biol Blood Marrow Transplant. 2013 Mar;19(3):410-7. doi: 10.1016/j.bbmt.2012.10.029. Epub 2012 Nov 2.

5.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).

Sirohi B, Cunningham D, Norman A, Last K, Chau I, Horwich A, Oates J, Chong G, Wotherspoon A.

Hematology. 2007 Apr;12(2):149-53.

PMID:
17454196
6.

Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.

Villa D, Seshadri T, Puig N, Massey C, Tsang R, Keating A, Crump M, Kuruvilla J.

Haematologica. 2012 May;97(5):751-7. doi: 10.3324/haematol.2011.047670. Epub 2011 Dec 16.

7.

Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.

Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.

Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098.

PMID:
18443961
9.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers.

Ann Oncol. 2002 Oct;13(10):1628-35.

10.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.

Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D.

Br J Cancer. 2005 Apr 25;92(8):1352-7.

11.

High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.

Cocorocchio E, Peccatori F, Vanazzi A, Piperno G, Calabrese L, Botteri E, Travaini L, Preda L, Martinelli G.

Hematol Oncol. 2013 Mar;31(1):34-40. doi: 10.1002/hon.2014. Epub 2012 Mar 30.

PMID:
22473680
12.

Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.

Yim KL, Ashley S.

Med Oncol. 2012 Dec;29(5):3535-9. doi: 10.1007/s12032-012-0309-6. Epub 2012 Jul 24.

PMID:
22825684
13.

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.

Binder D, Schweisfurth H, Grah C, Schäper C, Temmesfeld-Wollbrück B, Siebert G, Suttorp N, Beinert T.

Cancer Chemother Pharmacol. 2007 Jun;60(1):143-50. Epub 2006 Oct 10.

PMID:
17031643
14.

Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.

Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M.

Ann Hematol. 2011 Jun;90(6):685-91. doi: 10.1007/s00277-010-1113-z. Epub 2010 Nov 12.

PMID:
21072518
15.

ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

Labrador J, Cabrero-Calvo M, Pérez-López E, Mateos MV, Vázquez L, Caballero MD, García-Sanz R.

Ann Hematol. 2014 Oct;93(10):1745-53. doi: 10.1007/s00277-014-2114-0. Epub 2014 May 27.

PMID:
24863692
16.

Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.

Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF.

Ann Oncol. 2006 May;17 Suppl 4:iv25-30.

17.

[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].

Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.

Ai Zheng. 2005 Apr;24(4):465-9. Chinese.

PMID:
15820071
18.

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.

Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A.

Ann Oncol. 2005 Aug;16(8):1359-65. Epub 2005 Jun 6.

19.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A.

Cancer. 2008 Feb 15;112(4):831-6.

20.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A.

Ann Oncol. 2008 Jul;19(7):1312-9. doi: 10.1093/annonc/mdn052. Epub 2008 Mar 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk